By Fineline Cube 
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported Q1 2025 financials with global group revenues increasing by 6% year-on-year in constant currency terms to CHF 15.44 billion (USD 18.64 billion). Within that, pharma group sales grew by 8% YOY to CHF 11.95 billion (USD 14.43 billion), while diagnostics sales remained flat at 0% growth at CHF 3.49 billion (USD 4.21 billion).
Pharma Division Highlights
The pharma division’s key growth drivers were identified as breast cancer drug Phesgo (pertuzumab/trastuzumab/hyaluronidase), ophthalmology drug Vabysmo (faricimab), allergy and asthma therapy Xolair (omalizumab), hemophilia drug Hemlibra (emicizumab), and influenza drug Xofluza (baloxavir marboxil). Together, they contributed CHF 3.6 billion (USD 4.3 billion) in sales, an increase of CHF 0.7 billion (USD 845 million) from the same quarter in 2024.
Regional Performance
Pharmaceutical sales increased across major regions. In the United States, sales were up 6% YOY to CHF 6.22 billion (USD 7.5 billion). Europe saw a 5% increase to CHF 2.32 billion (USD 2.8 billion). Japan reported a 3% rise to CHF 671 million (USD 810 million). International markets, including China, saw the most significant growth at 18%, reaching CHF 2.73 billion (USD 3.3 billion). China alone contributed 14% to the international sales growth, driven by demand for Xofluza and Phesgo.-Fineline Info & Tech